



Biomega whitepaper reveals Salmon Peptides could have positive role in supporting weight management

There is increasing science-backed evidence available that shows how functional food ingredients and supplements can reduce the risk of obesity. To find out more, you can download our whitepaper [here](#).

01.07.2020

Download the whitepaper by filling in your details [here](#).

Biomega Group ('Biomega'), a leading biosciences company producing high-quality ingredients for the health and nutrition sectors, has released a new whitepaper discussing how bioactive salmon peptides could help to manage weight and minimise the risk factors associated with human and pet obesity.

According to the World Health Organization ('WHO'), worldwide human obesity has nearly tripled since 1975, with more than 1.9 billion adults classed as overweight and 650 million of these being obese. In parallel, pet obesity is on the rise too. The US Association for Pet Obesity Prevention ('APOP') has stated that up to 59% of dogs and cats are overweight, with recent studies suggesting that approximately 21% of canines are classed as overweight six months after birth.

Bjørn Liaset, Director of R&D at Biomega, said: "With global obesity levels in humans and animals rising year-on-year, there is a growing demand for functional food ingredients that have demonstrated their efficacy to help manage weight through safe, secure and science-backed studies.

"Our whitepaper explores how salmon protein hydrolysates can help to manage weight and combat health conditions relating to obesity in humans and animals. Considering substantial scientific evidence and reference to several published studies, the document outlines how bioactive salmon peptides can theoretically reduce inflammation in visceral adipose tissue and significantly decrease body mass index."

Entitled, 'Salmon Peptides and their potential role in weight management', the whitepaper is the second in a series of releases from Biomega explaining the scientific advantages salmon bioactive peptides could have on human and animal wellbeing. The whitepaper, which follows the company's first document on cardiovascular health, is available to download for free by completing the website form.

"As leaders in the biosciences industry, it's critical that we use this science-backed evidence to positively contribute to the wellbeing of humans and animals," Marianne Warnaer, Director of Global Sales at Biomega, adds. "Biomega is working with key industry players and brands to deliver safe and trusted salmon peptides to not only help improve the quality of life, but to prevent further health complications. With our sustainable food ingredients, we value vitality, value today and value tomorrow."

To download the whitepaper, please fill out your details [here](#). For more information on Biomega, please visit <https://biomegagroup.com/>.

About Biomega Group

The Biomega Group aspires to become the leading partner for innovative high-quality ingredients to the health & nutrition industry. Biomega's business model is fully sustainable and uses proprietary biotech to transform high quality raw material into premium food and feed ingredients. In its modern food grade biorefinery in Norway, Biomega produces hydrolyzed salmon proteins (salmon peptides), salmon meal and salmon oil. Biomega invests continuously in R&D to ensure best-in-class technology and respond to



customers' needs, including traceability and sustainability. The Biomega Group is a portfolio company of AMERRA Capital Management.

About AMERRA Capital Management

AMERRA is an independent asset management firm, providing strategic capital to upstream and midstream food and agri-businesses in Europe and the Americas. AMERRA brings unique value to its portfolio companies through its extensive network, in depth knowhow and a sole focus on the field. Throughout its dedicated strategies of private credit, special situations, and private equity, AMERRA adheres to best Environmental & Social practices and belongs to the United Nations Environment Program – Finance Initiative. Backed by long-term institutional capital with more than US\$ 1.7bn in assets under management, AMERRA has invested over \$5.2 billion since its inception in 2009. For more information about AMERRA please visit www.amerracapital.com.

Contact

David Gould
Head of Investor Relations and Capital Markets
AMERRA Capital Management
+1 (212) 710-8023
dgould@amerracapital.com